07:09 AM EDT, 10/23/2024 (MT Newswires) -- Boston Scientific ( BSX ) reported Q3 adjusted earnings Wednesday of $0.63 per share, up from $0.50 a year earlier.

Analysts polled by Capital IQ expected $0.59.

Net sales for the quarter ended Sept. 30 were $4.21 billion, compared with $3.53 billion a year earlier.

Analysts polled by Capital IQ expected $4.04 billion.

The company said it expects Q4 adjusted EPS of $0.64 to $0.66 and net sales growth of 16.5% to 18.5%. Analysts polled by Capital IQ expect $0.64 in adjusted EPS on revenue of $4.28 billion.

Boston Scientific ( BSX ) said it now expects full-year adjusted EPS of $2.45 to $2.47, from the previous range of $2.38 to $2.42, and net sales growth of about 16.5%, from its previous forecast of 13.5% to 14.5%. Analysts polled by Capital IQ expect $2.41 in adjusted EPS on revenue of $16.29 billion.

Price: 88.99, Change: +0.98, Percent Change: +1.11